(Q44168101)

30 November 2017

0 references

Does hormone treatment added to radiotherapy improve outcome in locally advanced prostate cancer?: meta-analysis of randomized trials (English)

1 reference

Adaptive radiation therapy

30 November 2017

main subject

0 references

1 reference

6

1 reference

30 November 2017

Emilio Bria

1

0 references

Diana Giannarelli

object named as

Diana Giannarelli

3

0 references

author name string

Federica Cuppone

2

1 reference

30 November 2017

Michele Milella

4

1 reference

30 November 2017

Enzo Maria Ruggeri

5

1 reference

30 November 2017

Paola Pinnarò

7

1 reference

30 November 2017

Edmondo Terzoli

8

1 reference

30 November 2017

Francesco Cognetti

9

1 reference

30 November 2017

Paolo Carlini

10

1 reference

30 November 2017

language of work or name

English

0 references

publication date

1 August 2009

1 reference

30 November 2017

1 reference

30 November 2017

volume

115

1 reference

30 November 2017

issue

15

1 reference

30 November 2017

page(s)

3446-3456

1 reference

Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate

30 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24392

Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma--long-term results of phase III RTOG 85-31.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24392

Confidence intervals for the number needed to treat

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24392

Report of a multicenter Canadian phase III randomized trial of 3 months vs. 8 months neoadjuvant androgen deprivation before standard-dose radiotherapy for clinically localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24392

Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24392

Androgen deprivation therapy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24392

7 January 2021

The 1989 patterns of care study for prostate cancer: five-year outcomes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24392

7 January 2021

Cancer statistics, 2008

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24392

7 January 2021

Predicting long-term survival, and the need for hormonal therapy: a meta-analysis of RTOG prostate cancer trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24392

7 January 2021

Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24392

7 January 2021

6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24392

7 January 2021

Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24392

7 January 2021

The efficacy and sequencing of a short course of androgen suppression on freedom from biochemical failure when administered with radiation therapy for T2-T3 prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24392

7 January 2021

Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24392

7 January 2021

The addition of bicalutamide 150 mg to radiotherapy significantly improves overall survival in men with locally advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24392

7 January 2021

Time to biochemical failure and prostate-specific antigen doubling time as surrogates for prostate cancer-specific mortality: evidence from the TROG 96.01 randomised controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24392

7 January 2021

Meta-analyses of randomised clinical trials in oncology.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24392

7 January 2021

Benefit of taxanes as adjuvant chemotherapy for early breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24392

7 January 2021

Interpreting Measures of Treatment Effect in Cancer Clinical Trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24392

7 January 2021

Magnitude of benefit of adjuvant chemotherapy for non-small cell lung cancer: meta-analysis of randomized clinical trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24392

7 January 2021

Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24392

7 January 2021

What kind of evidence do patients and practitioners need: evidence profiles based on 5 key evidence-based principles to summarize data on benefits and harms

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24392

7 January 2021

Evidence profiles for breast cancer: benefit/harms data based on the totality of randomized evidence

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24392

7 January 2021

Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24392

7 January 2021

Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24392

7 January 2021

Long-term androgen deprivation increases Grade 2 and higher late morbidity in prostate cancer patients treated with three-dimensional conformal radiation therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24392

7 January 2021

Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24392

7 January 2021

Influence of Androgen Suppression Therapy for Prostate Cancer on the Frequency and Timing of Fatal Myocardial Infarctions

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24392

7 January 2021

Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24392

7 January 2021

Diabetes and mortality in men with locally advanced prostate cancer: RTOG 92-02.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24392

7 January 2021

Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24392

7 January 2021

A systematic review and meta-analysis of randomised trials of neo-adjuvant hormone therapy for localised and locally advanced prostate carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24392

7 January 2021

Meta-analyses based on abstracted data: a step in the right direction, but only a first step.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24392

7 January 2021

Identifiers

DOI

10.1002/CNCR.24392

1 reference

30 November 2017

1 reference